At least one method and container are described for maintaining a target temperature within the container. The container generally includes a vacuum insulated body; a lid couplable to the vacuum insulated body; a heatsink, coupled to the lid, wherein a portion of the heatsink is positionable within the vacuum insulated body; and at least one thermoelectric cell coupled to the heatsink, wherein the at least one thermoelectric cell is operated to promote the transfer of heat between the inside of the container and the outside of the container to cool the inside of the container or to warm the inside of the container. The container may be arranged so that internal and external portions of the heatsink may be arranged in a decoupled position to reduce heat transfer therebetween.

Caps for sealing assemblies for sealing glass containers and maintaining container closure integrity at −80° C. or less are disclosed. The caps include a cap skirt having an annular body and a crimp region. The crimp region is a crimpable metal. The annular body of the cap skirt has a coefficient of thermal expansion (CTE) greater than a CTE of a metal consisting of aluminum, a stiffness greater than or equal to 2 times a stiffness of the crimp region, or both. The greater CTE, stiffness, or both of the cap skirt increase the seal pressure and contact area between the stopper and glass container when cooled to −80° C. or less. The caps enable the sealing assemblies to maintain a helium leakage rate of the sealed glass container of less than or equal to 1.4×10.sup.−6 cm.sup.3/s at −80° C. or less.

The present disclosure is directed to embodiments of a kiosk including a chassis having a patient compartment and a medication compartment. A patient does not have access to the medication compartment in the patient compartment. A dispense structure extends from the patient compartment to the medication compartment such that a dosage of medication may be dispensed to the patient when within the patient compartment. After the medication is dispensed to the patient, a medical professional observes the patient ingest the medication through a video conference display within the patient compartment. A biometric scanner may be in electrical communication with a lock in mechanical cooperation with a door hingedly coupled to the chassis to limit access to the medication compartment. An insulated safe with an internal chamber wherein the internal chamber's temperature is regulated. A medication is stored within the internal chamber of the insulated safe at a selected temperature by regulating the temperature within the internal chamber of the insulated safe.

A fining package for a glass composition may include cerium dioxide (CeO.sub.2) and tin oxide (SnO.sub.2). CeO.sub.2 may be present in an amount of 0.08 to 0.5 wt % of the glass composition, and SnO.sub.2 may be present in an amount of 0.02 to 0.23 wt % of the glass composition. The glass composition may be used to form glass tubing. The glass tubing may be used to form a pharmaceutical packaging. For example, the pharmaceutical packaging may comprise an ampoule. The fining package may further include chloride (Cl) in an amount of 0 to 0.03 wt % of the glass composition. In some instances, the fining package may be Cl-free. In some instances, the fining package may be F-free. The glass composition may comprise a borosilicate glass composition. The glass composition may comprise an aluminosilicate glass composition.

Drug delivery system, injection device, transfer apparatus, vial holder and method of administering and transferring are disclosed which provide for passive warming of chilled injectable transferred through the transfer apparatus and into the injection device. The injection device may include a skin-facing surface including a skin boundary displacement extension or structure around a needle injection site to create a high pressure zone in the tissue. Radio frequency tracking and monitoring features for tracking patient compliance also may be provided.

The present disclosure relates to a drug delivery device, comprising a shell adapted to contain one of a plurality of medicament containers prefilled with different deliverable volumes of a medicament. The shell is transparent at least in an area adapted to contain the medicament container, and a label adapted to be arranged on the shell. The label comprises a foil having a first surface and a second surface, which is adapted to be connected to the shell. At least one cutout or transparent area is arranged in the foil adapted to be placed on the shell such that a medicament container arrangeable or arranged within the shell is visible through the cutout or transparent area. The cutout or transparent area exhibits a size adapted to allow inspection of the deliverable volume of medicament within the medicament container when the label is applied to the shell.

The present invention provides a method for evaluating a processing deterioration level of a medical glass container, including (a) a step of imaging a surface of a medical glass container molded from a borosilicate glass tube to obtain an image, and (b) a step of analyzing a contrast of the image. The method is particularly useful to evaluate the amount of alkali substances which are deposited on the inner side surface of a medical glass container.

A dispenser actuator assembly (100) for actuating a dispenser (10) is disclosed. The dispenser (10) is in the form of a glass ampoule assembly (10) having a rupturable glass ampoule (12) containing a flowable material (M). The glass ampoule (12) is contained within an outer container (14) wherein the outer container (14) has a first open end (22) and a second closed end (24). The glass ampoule assembly (10) has an applicator (16) positioned in the first open end (22). The dispenser actuator assembly (100) has a base member (102) configured to mount on the outer container (14). The dispenser actuator assembly (100) also has an actuator assembly (104) operably connected to the base member (102) wherein the actuator assembly (104) has a first actuator arm (132a) and a second actuator arm (132b) each pivotally connected to the base member (102). The first actuator arm (132a) and the second actuator arm (132b) extend from the base member (102) in generally opposed relation defining a first position, or neutral position. The first actuator arm (132a) has a first protrusion (150a) depending therefrom and the second actuator arm (132b) has a second protrusion (150b) depending therefrom. The first actuator arm (132a) and the second actuator arm (132b) are pivotable from the first position towards one another to a second position, or actuating position, that is configured such that the first protrusion (150a) engages the outer container (14) and the second protrusion (150b) engages the outer container (14) to crush the glass ampoule (12) wherein the flowable material (M) is configured to be dispensed from the glass ampoule assembly (10).

A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, a flange extending from the neck, and a sealing assembly. The flange includes an underside surface extending from the neck, an outer surface extending from the underside surface, the outer surface defining an outer diameter of the flange, and an upper sealing surface extending between the outer surface and an inner surface defining an opening in the sealed pharmaceutical container. The sealing assembly includes a stopper and a metal-containing cap securing the stopper to the flange. The stopper includes a sealing portion extending over the upper sealing surface of the flange and covering the opening, and a rim extending at least partially along the outer surface of the flange.

A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (T.sub.g) that is greater than or equal to −70° C. and less than or equal to −45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10.sup.−6 cm.sup.3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to −45° C.